

Supplemental Figure 1. *In vivo* biodistribution of ^{18}F-FBZA in B16F10, A375M and U87MG tumor bearing mice and ^{18}F-FDG in B16F10 tumor bearing mice. Data are expressed as the percentage administered activity (injected dose) per gram of tissue (%ID/g) after intravenous injection of ^{18}F-FBZA or ^{18}F-FDG (100 μCi) at designated time points (n = 3 for each group). **(A)** ^{18}F-FBZA uptake in %ID/g. **(B)** ^{18}F-FBZA tumor-to-organ ratios. **(C)** ^{18}F-FDG uptake in %ID/g. **(D)** ^{18}F-FDG tumor-to-organ ratios (T represents for Tumor).



Supplemental Figure 2. *In vivo* biodistribution of intravenously injected ^{18}F-FBZA measured by using ROI analysis of dynamic small-animal PET data sets in C56BL/6 mice bearing B16F10 tumors (n = 3). Rapid uptake and clearance of ^{18}F-FBZA were observed in both liver and kidney. Rapid tumor uptake and sustained retention for the probe was also found. Error bars were omitted for better visibility.



Supplemental Figure 3. Representative decay-corrected coronal small-animal μPET images of ^{18}F-FBZA in eyes of C57BL/6 (A) *vs.* nude mouse (B). Eyes lit up in C57BL/6 mouse.